#USA #Miami #Immorta Bio #multi-omics #AI Precision Medicine

Immorta Bio's Vision for Precision Medicine

In a significant advancement for healthcare, Immorta Bio, in conjunction with Theriome Inc. and the American Board of Precision Medicine, has published a key Perspective article in the Journal of Translational Medicine. This publication, titled "Aspiration to Architecture Multi-Omics, AI, Digital Twins, and Blockchain for P4 Medicine", outlines how technologies can coalesce to realize the long-discussed goals of Predictive, Preventive, Personalized, and Participatory (P4) medicine. This ambitious initiative seeks to create a practical roadmap to transition P4 medicine from a conceptual framework into a clinically actionable model.

Gap in Clinical Implementation

Despite discussions surrounding P4 medicine for nearly 20 years, realizing its potential within clinical settings has remained significantly limited. The authors of the article argue that fruitful implementation necessitates the synergistic integration of four essential technologies:

• - Multi-Omics: This allows for a deep dive into biological insights that encompass individual variability.
• - Artificial Intelligence (AI): By processing complex biological data, AI can convert it into clinical actions.
• - Digital Twins: This technology models individual treatment strategies, providing a simulation before actual medical intervention occurs.
• - Blockchain: Ensures secure data ownership and sharing, empowering patients to control their health data.

When unified, these technologies can help create a healthcare ecosystem that is not only interconnected but continuously evolves to support personalized and preventative medical practices.

Metabolomics as Proof of Concept

As a proof of concept, the publication shares findings from exploratory metabolomic research involving over 2,000 individuals, highlighting nine metabolites that exhibit consistent changes correlated with aging. Such data underline the potential of multi-omics to offer dynamic biomarkers, which could further aid in tracking biological aging and therapeutic responses in real-time, representing a crucial step in personalized healthcare.

Statements from Experts

Dr. Anil Bajnath, Head of the American Board of Precision Medicine, stresses the necessity for a cohesive framework to incorporate multi-omics, digital innovations, and patient data control into healthcare. He stated, "For years, precision medicine has been discussed primarily as a concept rather than a complete clinical system."

Echoing this sentiment, Dr. Boris N. Reznik, CEO of Immorta Bio, emphasized the vision of a harmonious ecosystem where different facets of healthcare, including molecular profiling, AI applications, and secure data management, work collectively to foster effective healthcare solutions. He remarked, "The future of medicine will not be built around isolated biomarkers or standalone AI models."

Immorta Bio's Commitment

Dr. Thomas E. Ichim, President and Chief Scientific Officer at Immorta Bio, confirmed that the organization is actively pursuing this integrated model. Their flagship project, SenoVax™, leverages AI and computational biology, targeting cellular senescence, signifying a shift to more personalized healthcare responses.

This collaborative effort among Immorta Bio, Theriome, and the American Board of Precision Medicine reflects a concerted push towards a future where healthcare becomes more predictive, preventive, personalized, and participatory. By bridging the gap between technology and healthcare, they are paving the way towards innovative therapeutic strategies that target the complexities of aging and its related diseases.

About the Companies

Immorta Bio

Immorta Bio, Inc. is a biotechnology company specializing in developing pioneering therapies aimed at the underlying biological processes of aging. Its therapeutic platforms, SenoVax™ and StemCellRevivify™, showcase innovative solutions aimed at improving regenerative capacity and combating diseases related to aging.

American Board of Precision Medicine

The American Board of Precision Medicine is a non-profit organization dedicated to pioneering the education and clinical application of precision medicine.

Theriome

Theriome Inc. focuses on systems biology, aiming to make P4 medicine actionable. With technologies that provide real-time functional assessments of individual health, Theriome seeks to redefine how wellness is perceived and approached.

In conclusion, this publication marks a notable step towards shaping a comprehensive future for healthcare, embodying the principles of precision medicine through the integration of advanced technological frameworks.